Posters

Evaluation of stereopsis for blended vision variants with refractive MIOL compared to phakic eyes

Poster Details

First Author: D. Breyer GERMANY

Co Author(s): H. Kaymak   K. Klabe   P. Hagen   F. Kretz   G. Auffarth        

Abstract Details

Purpose:

In order to improve near vision, bifocal or EDOF IOLs with good far and intermediate vision can be implanted in a blended vision variant, where the target refraction in the nondomiant eye is set to approximately -1.5D. The aim of this retrospective analysis was to assess the question whether the patients also benefit from this variant with regard to stereoscopic vision.

Setting:

All MIOL implantations were performed at the Breyer-Kaymak-Klabe Eyesurgery in Duesseldorf, Germany. All considered patients underwent bilateral implantation of refractive MIOLs from the following list: Comfort (bifocal, 1.5D addition, Oculentis), Mplus (bifocal, 2.0D addition, Oculentis), MiniWell (EDOF, Sifi) WIOL-CF (EDOF Medicem)

Methods:

The target refraction was emmetropia in the dominant eye and in the nondominant eye it was either approximately -1.5D (Blended Vision, 30 patients) or emmetropia (Emmetropic Vision, 30 patients). As a third group we considered phakic eyes (60 patients). Stereopsis was tested using the Stereo Fly Test (Precision Vision), which was positioned at a distance of 16inches. Analogue to logMAR-values for visual acuity, we calculated the logartihm of the minimum angle of stereopsis (logMAS) and compared the mean values of all groups.

Results:

The minimum angle of strereopsis was 0.29logMAS, 0.05logMAS and -0.05logMAS in the group with emmetropic vision, blended vision and phakic eyes, respectively. Comparing areas under binocular defocus curves (MIOL-capacity), blended vision with Comfort MIOLs achieved the highest binocular defocus capacity of 101%.

Conclusions:

Stereoscopic vision is significantly better for blended vision than for emmetropic vision implantation variants. Phakic eyes outperform both groups, whereby these differences were not clinically recognized by patients.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company